The FDA has granted Bcl-2 inhibitor APG-2575 orphan drug eligibility for the treatment of chronic lymphocytic leukemia.

Chronic lymphocytic leukemia (CLL) is an adult leukemia characterized by the gradual accumulation of abnormal lymphocytes in exost blood, bone marrow, and lymphatic tissue.
the American Cancer Society estimates that by 2020, about 4,060 people will die from the disease each year in the United States.
Biotech company Aachen Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has awarded the new Bcl-2 inhibitor APG-2575 orphan drug title (ODD) for the treatment of chronic lymphocytic leukemia (CLL).
APG-2575 is a new oral Bcl-2 selective inhibitor developed by Asaan Pharmaceuticals.
APG-2575 is able to selectively block Bcl-2 to restore normal apoptosis in cancer cells, thereby treating various blood system malignancies.
APG-2575 is one of the few Bcl-2 selective inhibitors in the world and the first Bcl-2 selective inhibitor to be developed in China, and has entered clinical trials in China.
APG-2575 as a single drug or in a combined treatment with other therapeutic drugs relapsed/refractic CLL/SLL (small lymphocyte lymphoma) has been conducted in China, Australia and the United States in a number of IB / II clinical studies.
.